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Rising numbers of patients with cardiovascular diseases and limited availability of donor
hearts require new and improved therapy strategies. Human atrial appendage-derived
cells (hAACs) are promising candidates for an allogeneic cell-based treatment. In
this study, we evaluated their inductive and modulatory capacity regarding immune
responses and underlying key mechanisms in vitro. For this, cryopreserved hAACs
were either cultured in the presence of interferon-gamma (IFNγ) or left unstimulated.
The expression of characteristic mesenchymal stromal cell markers (CD29, CD44,
CD73, CD105, CD166) was revealed by flow cytometry that also highlighted a
predominant negativity for CD90. A low immunogeneic phenotype in an inflammatory
milieu was shown by lacking expression of co-stimulatory molecules and upregulation
of the inhibitory ligands PD-L1 and PD-L2, despite de novo expression of HLA-DR.
Co-cultures of hAACs with allogeneic peripheral blood mononuclear cells, proved their
low immunogeneic state by absence of induced T cell proliferation and activation.
Additionally, elevated levels of IL-1β, IL-33, and IL-10 were detectable in those cell culture
supernatants. Furthermore, the immunomodulatory potential of hAACs was assessed
in co-cultures with αCD3/αCD28-activated peripheral blood mononuclear cells. Here,
a strong inhibition of T cell proliferation and reduction of pro-inflammatory cytokines
(IFNγ, TNFα, TNFβ, IL-17A, IL-2) were observable after pre-stimulation of hAACs with
IFNγ. Transwell experiments confirmed that mostly soluble factors are responsible
for these suppressive effects. We were able to identify indolamin-2,3-dioxygenase
(IDO) as a potential key player through a genome-wide gene expression analysis and
could demonstrate its involvement in the observed immunological responses. While
the application of blocking antibodies against both PD-1 ligands did not affect the
immunomodulation by hAACs, 1-methyl-L-tryptophan as specific inhibitor of IDO was
able to restore proliferation and to lower apoptosis of T cells. In conclusion, hAACs
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represent a cardiac-derived mesenchymal stromal-like cell type with a high potential for
the application in an allogeneic setting, since they do not trigger T cell responses and
even increase their immunomodulatory potential in inflammatory environments.
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INTRODUCTION
Cardiovascular diseases are the leading cause of morbidity and
mortality worldwide with ischemic heart disease alone being
responsible for almost 1.8 million deaths per year in Europe (20%
of all deaths; European Heart Network, 20171). Even though
there is a range of existing therapeutic strategies available, which
have beneficial effects on the improvement of life quality and
the extension of lifespan in cardiovascular patients, they often
leave them with no other causal therapy option than heart
transplantation (1, 2).
Numerous attempts using a variety of different cell sources
were initiated over the last 20 years for development of
new therapeutic treatments to induce cardiac regeneration (3).
Particularly autologous cell sources, ranging from hematopoietic
cells (4), over mesenchymal stromal cells (MSCs) from different
tissues (5–7), to various cardiac progenitor cells (CPCs) (8–11)
have been heavily investigated in this context. Specifically, the use
of CPCs led to promising results: animal models of myocardial
infarction demonstrated improved cardiac function after cell
transplantation (12) and even first clinical studies in humans
(SCIPIO and CADUCEUS trials) were able to show moderately
increased regeneration of cardiac tissue (13–16).
An alternative mesenchymal-like cardiac cell type for an
autologous therapeutic application in heart injury, are so called
cardiac-derived adherent proliferating cells (CardAPs). This
unique cell type derived from endomyocardial biopsies shares
typical characteristics with MSCs but clearly distinguishes itself
from all other cell types used so far in cell therapeutic application.
CardAPs are positive for CD44, CD73, CD105, and CD166 but
express neither the hematopoietic markers CD14, CD34 and
are strikingly low for the marker CD90, which is otherwise
characteristic for MSCs and fibroblasts (17). These cardiac-
derived cells demonstrated increased regenerative potency by
mediating angiogenesis and cardiomyogenesis, reducing cardiac
hypertrophy and exhibiting immunomodulatory capacities to
induce an anti-inflammatory environment (18–20). Our own
immunological in vitro tests with these mesenchymal-like
CardAPs proved their low immunogeneic status as well as
1European Cardiovascular Disease Statistics 2017 edition. CVD Statistics 2017
(2017). Available online at: http://www.ehnheart.org/cvd-statistics/cvd-statistics-
2017.html (accessed: February 02, 2019).
Abbreviations: 1-MT, 1-methyl-L-tryptophan; CardAPs, cardiac-derived
adherent proliferating cells; CD, cluster of differentiation; CFSE,
carboxyfluorescein succinimidyl ester; COX-1, cyclooxygenase 1; CPCs, cardiac
progenitor cells; hAACs, human atrial appendage-derived cells; HLA, human
leukocyte antigen; HUVECs, human umbilical vein endothelial cells; IDO,
indolamine-2,3-dioxygenase; IFNγ, interferon-gamma; IL, interleukin; MFI, mean
fluorescence intensity; MSCs, mesenchymal stromal cells; PBMCs, peripheral
blood mononuclear cells; PD-L, programmed death ligand; TGFβ, transforming
growth factor beta; TLR3, toll-like receptor 3; TNF, tumor necrosis factor.
the capacity to modulate the immune system toward an
anti-inflammatory state (21). However, recent clinical phase-
I studies with mesenchymal cell types highlighted some
of the fundamental limitations of autologous cell sources
(22). Manufacturing a sufficient amount of a patient-specific
cell product is time consuming, thus preventing immediate
availability in acute situations. Additionally, harvesting from
elderly diseased patients with co-morbidities raised further
concerns regarding the functional integrity and overall survival
of obtained cells (23). Furthermore, it is the recent scientific
consensus that every stromal cell source has to be considered
as an independent entity and requires a comprehensive
phenotypical and functional characterization using standardized
protocols, with a particular focus on their immunological
properties and immunomodulatory potency (24). This would
help to identify an adequate cell source or cell subset and to
promote the appropriate and safe application as a cell therapeutic
or even as cell free products based on paracrine released vesicles
or mediators.
For that reason, it is essential to evaluate the potential use of
allogeneic cardiac-derived cells, since they can be harvested from
healthy donors, have the benefit of being available at any time and
can be assessed and manipulated in advance to fit the patient’s
needs (25). This might be important, since the transplantation
of allogeneic cells or tissues always poses the risk of recognition
by the recipient’s immune system and induction of unwanted
inflammatory responses by secretion of allo-antibodies (26, 27)
or even T cell-mediated rejection responses (28, 29).
Experimental data by others with a cardiac-derived
mesenchymal-like cell type indicated that those cryopreserved
c-Kit+ CPCs displaying low immunogeneic properties, were
able to reduce local inflammatory processes and limit T cell
proliferation in already ongoing immunoreactions in vitro (30).
Additionally, the phase-I/-II CAREMI trial already proved
the principal safety of allogeneic cell transplantation with
previously mentioned c-Kit+ selected CPCs by absence of major
adverse effects after intracoronary injection (31). However, the
overall benefit in cardiac improvement remains ambiguous and
demands the evaluation of additional allogeneic cell sources.
Our group recently described the atrial appendage as a
potential new cell source for human atrial appendage-derived
cells (hAACs) that are a CD90low cell product with similar
pro-angiogenic characteristics compared to the endomyocardial-
derived CardAPs (32). hAACs can be easily isolated from cardiac
tissue and would allow allogeneic treatment for a substantial
number of patients. These cells represent a mesenchymal-
like cardiac-derived cell type based on the expression of
the characteristic markers CD29, CD44, CD73, CD105, and
CD166, but predominantly lack expression of CD90 at the
same time. Precisely, this CD90low phenotype could provide
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a beneficial tool for the enhanced repair capacity of a
cell product, since it was shown that CD90 expression on
cardiosphere-derived cells is negatively correlated with the scar
size of injured heart tissue after cell application in myocardial
infarction (33). In addition, first studies with hAACs in a
mouse model of Coxsackievirus B3 (CVB3)-induced myocarditis
could demonstrate, that intravenous application was able to
improve the left ventricular heart function and contractility
as well as to decrease tissue collagen I expression. In this
experimental mouse study, immunomodulatory effects were
also confirmed by detecting reduced levels of TGFβ-producing
CD68+ cells and regulatory T cells in the spleen of treated
animals (34).
To ensure the safety and efficacy of this new hAAC product for
an allogeneic transplantation in humans, it is crucial to determine
whether these cells trigger immune responses in an inflammatory
scenario, as seen in cell transplantation. Therefore, we aimed to
assess the immunological properties of this defined cell product,
test their interaction with cells from the adaptive immune system
in vitro and gain insights into the underlying mechanism of
action. First, we confirmed a mesenchymal-like surface marker
expression profile after cryopreservation and assessed changes of
the immune phenotype under inflammatory conditions. Second,
hAACs were evaluated in immune cell co-cultures to study
potential immunogeneic properties and the capacity to modulate
adaptive immune responses. We could identify several potential
molecules explaining the observed immune modulatory effects
by a genome-wide gene expression analysis. Finally, our data
revealed that indolamine-2,3-dioxygenase (IDO) is a key player
of the immunomodulation by hAACs mediating the inhibition
of T cell proliferation and the induction of their apoptosis.
MATERIALS AND METHODS
Isolation and Culture of Human Atrial
Appendage-Derived Cells (hAACs)
Right atrial appendages, that were obtained during open-
heart surgery at Deutsches Herzzentrum Berlin from eight
patients, were used to generate hAACs as previously described
(32). Briefly, the right atrial appendages were reduced to
fragments of 1 mm3 and cultured in Iscove’s Modified Dulbecco’s
Medium (IMDM; Biochrom, Berlin, Germany) containing
10% allogeneic human serum (German Red Cross, Berlin,
Germany), 100 U/mL penicillin and 100µg/mL streptomycin
(both from Biochrom). Outgrowing cells were harvested after
about 13 days with 0.05% trypsin/0.02% EDTA (Biochrom)
and then subjected to immunomagnetic sorting with CD90
microbeads (MACS; human CD90 MicroBeads kit, Miltenyi
Biotec, Bergisch Gladbach, Germany). The resulting CD90low
cell population was grown under standard culture conditions
(37◦C in 21% O2 and 5% CO2 atmosphere) at a density of
6000 cells/cm² in complete medium (cIDH) consisting of equal
amounts of IMDM/DMEM/Ham’s F12 (IDH; all Biochrom)
and supplemented with 5% male heat-inactivated human AB
serum (Sigma-Aldrich, St. Louis, MO, USA), 100 U/mL penicillin
and 100µg/mL streptomycin (Gibco R© Life Technologies, Grand
Island, NY, USA), 20 ng/mL basic fibroblast growth factor
and 10 ng/mL epithelial growth factor (both from Preprotech,
Hamburg, Germany) for further expansion of the purified cell
product. Subsequently, hAACs were cryopreserved for at least
6 months to mimic conditions of a cell bank. After thawing,
cells were routinely passaged once in cIDH medium before
performing assays and were used between passages 2 and 8.
Tissues were obtained according to the local guidelines of the
Charité - Universitätsmedizin Berlin as well as the Declaration of
Helsinki and the study was approved by the ethics committee of
the Charité - Universitätsmedizin Berlin (No. 4/028/12). Human
leukocyte antigen (HLA)-typing of the cells were performed in
the HLA-Laboratory of the Charité - Universitätsmedizin Berlin
by SSO-PCR (low) for HLA-A, HLA-B and HLA-DR. A list of all
HLA-typed cells is available in the Supplementary Table 1.
Culture of Human Umbilical Cord-Derived
Mesenchymal Stromal Cells (MSCs) and
Umbilical Vein Endothelial Cells (HUVECs)
Due to their known immunomodulatory potential as previously
described (35), human umbilical cord-derived MSCs were used
as control cells in the immune cell co-culture experiments.
Cells were kindly provided by Dirk Strunk’s laboratory at
the Institute of Experimental and Clinical Cell Therapy and
Spinal Cord & Tissue Regeneration Center, Paracelsus Medical
University (PMU) Salzburg, Austria and were obtained for
human cell and tissue sample collection from the Institutional
Review Board of the Medical University of Graz (protocol 19-
252 ex 07/08) as described (36). Umbilical cord samples were
collected from mothers that gave written informed consent
after full-term pregnancies in accordance with the Declaration
of Helsinki. After thawing, MSCs were grown in alpha-
modified minimum essential medium (alpha-MEM; Biochrom),
supplemented with 5% human male heat-inactivated AB serum
(Sigma-Aldrich), 2mM L-glutamine, 100 U/mL penicillin and
100µg/mL streptomycin (both from Gibco R© Life Technologies)
at 37◦C in 21% O2 and 5% CO2 atmosphere. HLA-Typing of
the donor cells was performed by SSP PCR using Olerup SSPTM
low-resolution kits (GenoVision Inc., Philadelphia, PA, USA).
HUVECs were used as positive controls in the immune cell
co-culture experiments (Cascade Biologics R©, Thermo Fisher
Scientific, Rochester, NY, USA and Lonza, Wakersville, MD,
USA). After thawing, HUVECs were cultured in EGM-2 (Lonza)
with 5% human male heat-inactivated AB serum (Sigma-
Aldrich), 100 U/mL penicillin and 100µg/mL streptomycin
(Gibco R© Life Technologies) for further expansion.
Both cell types were passaged once before performing assays
and were used between passages 2 and 8.
PBMC Isolation
Human peripheral blood mononuclear cells (PBMCs) were
isolated from buffy coats (German Red Cross, Berlin, Germany;
approved by the local Ethical Committee, EA1/226/14) by using
a Biocoll gradient (Biochrom), as previously described (37).
Briefly, following centrifugation at 800 g for 30min without
brake, PBMCs were harvested from the interphase and were
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washed three times with cold phosphate buffered saline solution
(PBS; Biochrom). Cells were cryopreserved for later experimental
use in liquid nitrogen. HLA-typing was performed in the HLA-
Laboratory of the Charité - Universitätsmedizin Berlin by SSO-
PCR (low) for HLA-A, HLA-B and HLA-DR.
Immunocytochemistry Analysis of hAACs
hAACs were plated on collagen I-coated (BD Biosciences,
San Jose, CA, USA) 24 well dishes (Falcon, BD Biosciences).
After incubation overnight, wells were washed three times
with Hank’s Balanced Salt Solution (HBSS; Gibco R© Life
Technologies) containing Mg2+ and Ca2+, fixed with 4%
paraformaldehyde (PFA; Roth, Karlsruhe, Germany) for 10min
at room temperature and washed twice with HBSS. Subsequently,
the cells were incubated with 5µg/mL wheat germ agglutinin
(WGA; Biotium, Fremont, CA, USA) for 10min at 37◦C. After
washing twice with HBSS, nuclei were counterstained for 15min
at room temperature with 4,6-diamidino-2-phenylindole (DAPI;
Molecular probesTM, Thermo Fisher). Images were taken with
an Operetta R© High Content Imaging System and image analysis
performed by the ColumbusTM Image Data Storage and Analysis
System (both from Perkin Elmer, Waltham, MA, USA).
Fluorescence Staining of Cells and Flow
Cytometry (FACS)
Non-adherent PBMCs were resuspended by pipetting, and
adherent hAACs were first harvested using a 0.05% trypsin
solution with EDTA (Gibco R© Life Technologies) and transferred
to 5mL FACS tubes (Falcon, BD Biosciences). Staining procedure
was performed as previously described (37). Briefly, cells were
washed once with cold PBS, resuspended in a final volume of
50 µL antibody mix in cold FACS buffer [PBS supplemented
with 1% fetal calve serum (FCS; both Biochrom)] and incubated
for 30min at 4◦C in the dark. A list of all used antibodies
and dyes as well as the respective dilution is available in the
online Supplementary Table 2. Antibody mixes also contained
the Live/Dead R© violet Staining Kit (Molecular probesTM, Thermo
Fisher Scientific) in order to exclude dead cells from the analysis.
After antibody incubation, the samples were washed with cold
FACS buffer and resuspended in 1% PFA (Roth, Karlsruhe,
Germany) in FACS buffer. Samples were kept at 4◦C in the
dark until measurement on a FACS Canto II device with
FACS Diva software (Becton Dickinson, San Jose, CA, USA).
Data analysis was performed using FlowJo software (TreeStar
Inc., Ashland, OR, USA; RRID:SCR_008520). Gating strategies
for the FACS-analysis of hAACs and PBMCs are shown in
Supplementary Figure 1. Expression of a marker is presented
either as percentage of positive cells against the unlabeled control
or as geometric mean of fluorescence intensity (MFI).
Kinetic Analysis of hAAC Surface
Marker Expression
hAACs were seeded on 24 well-plates (Costar R©, Corning
Incorporated, Kennebunk, ME, USA) at a density of 3 ×
105 cells and were cultured in cIDH medium overnight.
Afterwards, hAACs were either directly harvested for evaluation
of constitutive MSC marker expression (CD90, CD29, CD44,
CD73, CD105, CD166, CD14, CD31, CD45, c-Kit) or stimulated
with 100 ng/mL of interferon-gamma (IFNγ) or a combination
of 100 ng/mL IFNγ and 100 ng/mL tumor necrosis factor alpha
(TNFα; both from Miltenyi Biotec) for evaluation of the
immunological (HLA-ABC, HLA-E, HLA-DR, CD80, CD86, PD-
L1 and PD-L2) and characteristic MSC markers (CD90, CD29,
CD44, CD73, CD166). hAACs were stimulated and harvested
after one, 2 and 5 days, respectively for flow cytometric analysis
as described before.
hAAC/Immune Cell Co-cultures
hAACs from six different donors and control cultures with MSCs
and HUVECs were seeded on rat tail collagen I-coated (BD
Biosciences) 24 well plates (Costar R©, Corning Incorporated)
at a density of 2 × 105 cells. After attachment overnight, the
adherent cells were either stimulated with 100 ng/mL IFNγ
(Miltenyi Biotec) or left unstimulated for 48 h. Afterwards, the
confluent monolayers were irradiated with 60 Gray using a
gamma-radiation source (GSM GmbH, Leipzig, Germany) to
maintain a stable cell number throughout the assay. Human
HLA-mismatched PBMCs were thawed, washed three times with
cold PBS (Biochrom) and labeled with 5µM carboxyfluorescein
succinimidyl ester (CFSE; Biolegend, San Diego, CA, USA) for
3min. The staining reaction was then stopped by incubating
with cold heat-inactivated human AB serum (Sigma-Aldrich)
for 1min. After washing three times with cold PBS, 3 ×
105 CFSE-labeled PBMCs, that were a complete mismatch
to the respective hAAC donor, were added to the hAAC,
MSC and HUVEC cultures. The resulting co-cultures were
maintained in 1mL of very low endotoxin (VLE)-Roswell
Park Memorial Institute (RPMI; Biochrom), supplemented with
10% human male heat-inactivated AB serum (Sigma-Aldrich),
100x L-glutamine solution, 100 U/mL penicillin and 100µg/mL
streptomycin (all from Gibco R© Life Technologies). After 4
days, 250 µL of co-culture supernatant were taken for cytokine
detection and 750 µL of completely supplemented VLE-RPMI
were added to the cultures. Following seven days of incubation,
PBMCs were harvested, stained for human immune cell defining
surface markers and analyzed by flow cytometry.
Proliferation Based Immunomodulation
Assay
Analogous to the hAAC/immune cell co-culture analysis, hAACs,
MSCs and HUVECs were cultured on rat tail collagen I-
coated (BD Biosciences) 24 well plates (Costar R©, Corning
Incorporated) at a density of 2 × 105 cells in the presence or
absence of 100 ng/mL IFNγ (Miltenyi Biotec) for 48 h. Human
PBMCs were CFSE-labeled as mentioned before and activated
with a combination of 0.02µg/mL anti-CD3 (OKT3 antibody,
Janssen-Cilag, Neuss, Germany) and 0.03µg/mL anti-CD28 (BD
Biosciences). Lastly, 1 × 106 PBMCs were added to the cultures
in 2mL of completely supplemented VLE-RPMImedium. After 3
days, supernatants were taken for cytokine detection and PBMCs
were harvested, stained for human immune cell defining surface
markers and analyzed by flow cytometry.
Experimental settings were repeated under transwell
conditions. Here, hAACs were seeded at a density of 4 × 104
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cells at the bottom of rat tail collagen I-coated 24 well plates.
After stimulation with IFNγ, polycarbonate transwell inserts
with 0.4µm pore size (Costar R©, Corning Incorporated) were
initially equilibrated for 1 h at 37◦C with RPMI and subsequently
2× 105 CFSE-labeled PBMCs were seeded into the inserts. After
a co-culture time of 3 days at 37◦C in a 21% O2 and 5% CO2
atmosphere, PBMC were harvested for flow cytometric analysis
of proliferation and surface marker expression.
To selectively analyze the effects of either indoleamin-
2,3-dioxygenase (IDO) or both programmed death-1 (PD-1)
ligands (PD-L1 and PD-L2) in immune cell co-cultures with
hAACs, 1mM 1-methyl-L-tryptophan (1-MT; Sigma-Aldrich)
was provided 2 h prior to addition of CFSE-labeled or unlabeled
PBMCs and 5µg/mL of purified anti-PD-L1 and anti-PD-L2
antibodies (both Biolegend) were added 12 h before CFSE-labeled
or unlabeled PBMCs were added to the hAAC cultures.
Cytokine Detection Assays
Supernatants of mono- and co-cultures of hAACs, MSCs
and HUVECs from the proliferation induction experiments
were tested for IL-1β, IFNα, IFNγ, TNFα, MCP-1, IL-6, IL-
8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, and IL-33 using the
LegendplexTM human inflammation 13-plex panel (Biolegend).
The minimum detectable concentration of each cytokine is given
as 0.6–2.1 pg/mL. Samples were treated following manufacturer’s
instructions and measured with a FACS Canto II device
(Becton Dickinson).
Supernatants of hAAC co-cultures from the direct-contact
immunemodulation experiments were analyzed for their content
of IL-1β, IL-2, IL-5, IL-10, IL-13, IL-17A, TNFα, TNFβ, IFNγ,
and MDC by a multiplex assay using a Milliplex R© human multi-
analyte Luminex R© kit (Merck KGaA, Darmstadt, Germany).
Samples were treated following manufacturer’s instructions and
measured with a Bio-Plex R© 200 multiplex analysis device (Bio-
Rad R©, California, USA).
Genome-Wide Gene Expression Profile
Human GeneChip U133 Plus 2.0 (Affymetrix, Santa Clara,
CA, USA) was used for genome-wide gene expression profiling
of hAAC samples covering over 47,000 transcripts (54,765
probes in total including double entries). RNA samples of
unstimulated and IFNγ pre-stimulated hAACs were prepared
with GeneChip R© 3′ IVT Express Kit and GeneChip R©
Hybridisation, Wash and Stain Kit (Affymetrix) according
to the manufacturer’s instructions. In brief, 250 ng total RNA was
used for cDNA synthesis and subsequent in vitro transcription
(IVT) to amplified RNA (aRNA). 12.5 µg fragmented aRNA was
used for hybridization on the chip for 16 h at 45◦C. Finally, the
chips were washed, stained and scanned using the Affymetrix
Gene Chip Scanner 3000. Affymetrix GeneChip Operating
Software (GCOS) 1.4 was used to generate CEL data files, for
raw data processing and for calculation of signal intensity,
signal log ratio (SLR) and p-value of pairwise chip comparisons
AF/NP. Quality control and pre-processing was done in R2
with the package “affy” (38). Raw data were normalized and
log2-transformed using Robust Multi-array Average (RMA)
algorithm implemented in this package. Thousand probe sets
with the highest variances were selected in order to run a
principle component analysis. Differentially expressed probe
sets between the two treatment groups were selected by fitting
linear models to the data and Bayesian statistics were run as
implemented in the package “limma” (39). False discovery
rates were used to adjust raw p-values for multiple testing and
a minimal absolute log2-Foldchange of 1 was used for probe
set selection. Mapping of differentially expressed probesets
to genes and functional annotations of the DAVID database
(40, 41) was done using the package “clusterProfiler” (42).
Over-representation of differentially expressed genes in terms
of the category “Biological Process” of the gene ontology system
was done using the enrichDAVID()-function of this package.
The eight top ranking results of this analysis were shown as
GOcirc-plot using the “GOplot”-package (43).
RNA Extraction, cDNA Synthesis and
Quantitative Polymerase Chain
Reaction (qPCR)
Total RNA was extracted from unstimulated and IFNγ pre-
stimulated hAACs following 48 h of incubation using the
RNeasy R© Mini Kit (QIAGEN, Venlo, Netherlands) according
to the manufacturer’s protocol. After measuring the RNA
concentration with the NanoDrop 2000 spectrophotometer
(Thermo Fisher Scientific), cDNA was synthesized. The reverse
transcription reaction was performed using TaqManTM Reverse
Transcription Reagents Kit (InvitrogenTM, Thermo Fisher
Scientific). Briefly, the following components were combined
to perform a 20 µL reaction volume: nuclease-free water plus
total RNA (1000 ng/µL), RNase inhibitor (20 U/µL), Mg2Cl,
10x RT Buffer, Random Hexamer Primer Mix (50µM), dNTP
Mixture (2.5mM each dNTP) and Reverse Transcriptase (RT;
50 U/µL). Samples were incubated for 30min at 48◦C, 5min
at 95◦C and subsequently cooled down at 4◦C with a Thermo
Flex Cycler Block (Analytik Jena, Jena, Germany). After the RT-
PCR the concentration of the generated cDNA was measured
with the NanoDrop 2000 to ensure a functional template for the
subsequent qPCR. The qPCR was performed on a QuantStudio
6 Flex Real-Time PCR machine (Applied Biosystems, Thermo
Fisher Scientific) using the SensiMixTM SYBR No-ROX kit
(Bioline, London, UK). The thermal cycling conditions were
comprised of a 95◦C initial template denaturation for 20 s,
followed by 40 cycles of PCR by applying 95◦C for 15 s and 60◦C
for 20 s. Lastly, a final melt curve stage with 40 cycles comprising
of 95◦C for 15 s, 60◦C for 60 s and 95◦C for 15 s was performed.
Three technical replicates of each sample were analyzed for gene
expression of IDO1, LGALS9, TLR3, PD-L1, PD-L2, PTGS1, HLA-
G, and VCAM1. All of the used primer sequences are listed in
Table 1. The samples were normalized to the expression of the
2R Core Team. R: A Language and Environment for Statistical Computing. Vienna:
R Foundation for Statistical Computing (2018). Available online at: https://www.
R-project.org/
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TABLE 1 | The Primer sequences of selected immunomodulatory genes.










house keeping gene HPRT and data were analyzed using the
delta-delta Ct (11Ct) method. The final results are therefore
calculated as fold change of target gene expression in IFNγ pre-
stimulated hAAC samples relative to the unstimulated hAAC
reference samples to demonstrate upregulation of differentially
expressed genes.
Raman Trapping Microscopy
Raman spectral acquisition was conducted using a BioRam R©
system (CellTool GmbH, Tutzing, Germany) equipped with an
excitation laser wavelength of 785 nm and a laser power of 80
mW. The laser was focused through a 60x (NA 0.7) air objective.
In all samples, 500 single cells were randomly selected under
bright-field illumination and pinpointed for automatic spectra
retrieval. Raman spectra were taken from the cytoplasm using
accumulated scans of 3 × 10 s. Together with the spectra the x-
y-z coordinates as well as bright-field images of each measured
cell were stored. As control, 10 background measurements were
taken from each sample. To assess acquired Raman spectra,
multivariate data analysis was performed. Principal Component
Analysis (PCA) was used for visualizing the datasets. PCA was
implemented in Python 2.7, using the scikit-learn package (44).
PCA score plots were used to look for clusters among the data.
Circles in 2D scores plot depict 95% confidence intervals.
Statistical Analysis
Statistical Analysis and graph generation was performed with
GraphPad Prism 8.0 (Graphpad Software, La Jolla, USA;
RRID:SCR_002798). Statistical analyses were chosen that do rely
on non-parametric distribution, since all data sets were n ≤ 10.
Statistical differences between two groups with only one variable
were analyzed using the Mann-Whitney non-parametric t-test.
For more than two groups withmultiple variables, KruskalWallis
one-way analysis of variance (ANOVA) with Dunn’s post tests
were applied. Statistical differences between two or more groups
with more than two variables were analyzed using an ordinary
two-way ANOVA with the Sidak’s post-test. All results are shown
as mean ± SEM and asterisks were assigned to the p-values
in the following order: ∗p ≤ 0.05; ∗∗ p ≤ 0.01; ∗∗∗p ≤ 0.001;
∗∗∗∗p ≤ 0.0001.
RESULTS
Cryopreserved hAACs Show Typical
Characteristics for Cells of
Mesenchymal Origin
It is crucial for a potential allogeneic application of hAACs to
determine the general characteristics of these cells after long-term
cryopreservation. hAACs from eight right atrial appendages were
generated from outgrowth cultures by negative immunoselection
for CD90, expanded in cell culture and cryopreserved for
at least 6 months (Figure 1A). Thawed cells after 24 h in
cell culture showed their distinctive morphology with long
elongated cell bodies and fibroblast-like appearance (Figure 1B).
Flow cytometry analysis for characteristic surface markers of
mesenchymal cells confirmed the distinguishing marker profile
of these cells. The hAAC cell product expressed most of the
known mesenchymal stem- and progenitor markers (e.g., CD29,
CD44, CD73, CD105, and CD166), while lacking the expression
of the endothelial marker CD31, the hematopoietic markers
CD14, CD34, and CD45 as well as the cardiac progenitor marker
c-Kit (CD117) (Figure 1C). Yet, in contrast to classical fibroblasts
and mesenchymal stromal cells, only a small proportion of cells
was positive for CD90 (Figure 1D).
Inflammatory Priming Alters the Immune
Phenotype of hAACs
To investigate the surface marker profile in an inflammatory
milieu, that mimics the environmental site of cardiac injury,
hAACs were stimulated with 100 ng/mL of IFNγ for 48 h.
Initial experiments with stimulation by pro-inflammatory
cytokines (IFNγ or a combination with TNFα) for 1, 2, and
5 days, showed an increase in surface marker expression
in the majority of tested markers (HLA-ABC, HLA-DR,
PD-L1) with an overall maximum of up-regulation after 2
days (Supplementary Figure 2). Hence, the time point of 48-
h stimulation with an appropriate IFNγ concentration of
100 ng/mL was chosen to determine the relative expression
levels as normalized mean fluorescence intensities (MFI) for a
set of immunologically-relevant markers. Stimulation of hAACs
induced similar changes in the surface marker expression
of all six donors as shown in FACS histogram overlays
(Figure 2A) of one representative donor and summarized as
Frontiers in Immunology | www.frontiersin.org 6 July 2019 | Volume 10 | Article 1716
Diedrichs et al. Immunomodulation by Cardiac-Derived Mesenchymal Cells
FIGURE 1 | Characteristics of human atrial appendage-derived cells (hAAC). (A) The general procedure to generate hAACs is shown: right atrial appendages were
harvested from patients during open-heart surgery. The dissected tissue was minced into small pieces and cultured. Subsequently, the fragment‘s outgrowth was
harvested, immuno-magnetically sorted as CD90low cells and seeded again for further expansion of the desired purified hAAC product. The cells were cryopreserved
and long-term stored for later experimental use. (B) Representative immunofluorescence images show the characteristic morphology of one hAAC donor in a cell
culture plate after 12 h of incubation. Cell membranes (orange) were stained with wheat germ agglutinin (WGA) and nuclei (blue) with 4,6-diamidin-2-phenylindol (DAPI).
Scale bar represents 50 µm. (C) Generated hAACs were harvested by treatment with trypsin after passage four and stained with human-specific antibodies against
surface markers characteristic for cells of mesenchymal origin (CD29, CD44, CD73, CD105, CD166), markers for exclusion of hematopoietic contaminants (CD14,
CD31, CD34, CD45) and the cardiac progenitor marker c-Kit (CD117). Representative flow cytometry histograms of one hAAC donor are shown as fluorescence
intensity against cell counts for all tested markers, indicating the mean of fluorescence intensity (MFI) of positive cells (blue) compared to the unlabeled controls (gray)
for each marker. (D) The percentage of remaining CD90+ cells in the hAAC cell product is shown for one representative donor in a dot plot of CD90 against CD29.
normalized MFI values (Figure 2B) as well as percentages
of marker positive cells (Supplementary Figure 3). All donors
expressed HLA-class I (HLA-ABC, and partly HLA-E) and low
or negligible levels of HLA class II (HLA-DR) constitutively,
but significantly up-regulated both HLA-molecule classes
under IFNγ-stimulation. In contrast, co-stimulatory molecules
such as CD80 and CD86 were completely absent, even
under stimulation. Additionally, a significant increase of the
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FIGURE 2 | Immune phenotype of cryopreserved hAACs under constitutive and inflammatory conditions. (A) Representative histogram overlays for one hAAC donor
display the expression pattern for immunologically-relevant surface markers (HLA-ABC, HLA-E, HLA-DR, CD80, CD86, PD-L1, PD-L2). Cells were cultured for 48 h
without additional stimulation (hAAC; light red line) or in presence of 100 ng/mL human interferon-gamma (IFNγ hAAC; dark red line). After harvest by application of
trypsin, cells were stained with human-specific antibodies and analyzed by flow cytometry. Fluorescence intensity of marker expression is presented compared to the
unlabeled control (Control; filled gray curve). (B) Summarized hAAC surface marker expression data are presented as normalized mean of fluorescence intensities
(MFI), that are calculated based on the respective controls (set to one; dashed black line), and shown as mean + SEM (n = 6; three independent experiments with six
different hAAC donors). Differences between unstimulated hAACs and IFNγ hAACs were considered significant when **p ≤ 0.01 with the Mann-Whitney t-test.
MFI for the immunomodulatory PD-1 ligands (PD-L1 and
PD-L2) could be determined after stimulation with IFNγ
(Figure 2B). Both markers were shown to be expressed on
a considerable proportion of cells (Supplementary Figure 3).
However, stimulation with IFNγ did not led to alterations in
MFI or frequency of mesenchymal marker expression (CD29,
CD44, CD73) on hAACs and even CD90 remained unchanged
(Supplementary Figure 4).
hAACs Evade Recognition by Allogeneic T
Cells in vitro Even in an
Inflammatory Milieu
Next, we were interested in the response of T cells against
allogeneic hAACs due to their key role as mediators of
allo-recognition and rejection in adaptive immune responses.
Accordingly, we mimicked the in vivo situation by co-culturing
HLA-mismatched PBMCs with hAACs from six different donors
and investigated the induction of allogeneic T cell responses by
monitoring their activation as well as proliferation. The T cell
immune responses induced by MSCs and HUVECs have been
well-described in the literature and therefore both cell types were
used as controls for absent or induced responses, respectively.
As shown in the experimental setup (Figure 3A) hAACs as well
as MSCs and HUVECs were cultured with or without pre-
stimulation by IFNγ for 48 h, thereupon CFSE-labeled PBMCs
from healthy donors were added to the cultures. After 7 days
of co-culture, the surface marker expression and proliferation
of T cells were analyzed by flow cytometry. Compared to
the unstimulated PBMC control cultures, the presence of
unstimulated HUVECs significantly induced proliferation of
CD8+ T cells but had no effect on the CD4+ T cell compartment
(Figures 3B,C). However, pre-stimulation with IFNγ led to
highly elicited levels of both CD4+ and CD8+ T cell proliferation.
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FIGURE 3 | hAACs maintain a low-immunogeneic profile even in an inflammatory environment. (A) The experimental setup for analyzing hAACs immunogenicity in
immune cell co-cultures is illustrated: mesenchymal stromal cells from the umbilical cord (MSCs) as well as human umbilical vein endothelial cells (HUVECs) served,
(Continued)
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FIGURE 3 | respectively, as cellular controls [MSC (-); HUVEC (+)] and were cultured along with hAACs for 48 h in the presence or absence of 100 ng/mL IFNγ. The
cells were gamma-irradiated with 60 Gray before carboxyfluorescein succinimidyl ester (CFSE)-labeled, human leukocyte antigen (HLA)-mismatched peripheral blood
mononuclear cells (PBMCs) were either added to the adherent cell cultures of all three cell types or left alone as control. After 4 days of incubation, supernatants were
taken for cytokine detection using the LegendplexTM human inflammation panel and after 7 days PBMCs were harvested, stained with human immune cell specific
antibodies and analyzed flow cytometrically. Levels of CD4+ and CD8+ T cell proliferation were detected by determining reduced CFSE signal intensity (black square).
(B) Representative flow cytometry plots of proliferated CD4+ and CD8+ T cells are shown for all PBMC co-culture groups and PBMCs only (Control). (C) Summarized
proliferation data for CD4+ and CD8+ T cells are presented as mean ± SEM (n = 6; three independent experiments with six different hAAC donor). Groups were
considered significantly different compared to the Control when *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 with Kruskal Wallis ANOVA and Dunn’s post-test. (D) Measured
cytokine levels in [pg/mL] for TNFα, IL-10, IL-1β, and IL-33 are shown as mean ± SEM (n = 6). Cytokine levels of the PBMC control groups are depicted as dotted
gray line. Groups were considered significantly different when *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 with Kruskal Wallis ANOVA and Dunn’s post-test. Differences
between treatments were considered significant when #p ≤ 0.05; ##p ≤ 0.01 with ordinary two-way ANOVA and Sidak’s post-test.
A similar trend was observed in the activation status that was
revealed by significantly increased percentages of HLA-DR+ T
cells in the CD4+ and CD8+ subsets after IFNγ pre-stimulation
(Supplementary Figure 5). hAACs on the other hand displayed
low-immunogeneic properties analogous to the moderate levels
of induced T cell proliferation detected inMSC co-cultures. Both,
hAACs andMSCs did not induce significant changes in CD4+ or
CD8+ T cell proliferation after IFNγ pre-stimulation as well as
under unstimulated conditions (Figures 3B,C), neither did both
cell types lead to increased expression levels of the activation
marker HLA-DR on T cells (Supplementary Figure 5).
Additionally, supernatants were taken from co-cultures after
4 days of incubation and were evaluated for their content
of various cytokines. Summarized data for TNFα, IL-10, IL-
1β, and IL-33 are presented in Figure 3D. The amount of
the pro-inflammatory cytokine TNFα significantly increased in
IFNγ-stimulated HUVEC co-cultures. Contrarily, unstimulated
hAAC co-cultures exclusively showed elevated levels of IL-10
release, that significantly decreased with IFNγ pre-stimulation.
Significant increases of IL-1β concentrations were detected
in co-cultures of unstimulated and IFNγ-stimulated hAACs.
While the concentration of IL-33 also increased in unstimulated
hAAC cultures, IFNγ-triggered co-cultures only showed a
significant elevation compared to the cytokine levels secreted
by HUVECs. Contrary to TNFα and IL-10, mono-cultures of
hAACs already constitutively produced the cytokines IL-1β and
IL-33 (Supplementary Figure 6). Other cytokines measured, like
MCP-1 and IL-8, were also produced at a basal level by the
adherent cells and showed no inordinate changes in PBMC co-
cultures (Supplementary Figure 7). IFNα, IFNγ, IL-12p70, IL-
17A, IL-18, and IL-23 were not detectable or only at negligible
levels (data not shown).
Immunomodulatory Efficiency of hAACs Is
Considerably Enhanced After
IFNγ Treatment
Activation of T cells and the resulting inflammatory responses
after cardiac injury largely contribute to adverse remodeling and
development of chronic heart diseases in patients. We therefore
examined the ability of hAACs, either unstimulated or IFNγ pre-
stimulated, to modulate an already ongoing T cell response in co-
cultures with αCD3/αCD28 activated PBMCs. In parallel PBMC
co-cultures with both control cell types (HUVECs and MSCs)
were performed. After 72 h of co-culture, proliferation rates of
CD4+ and CD8+ T cells and cytokine release were analyzed.
As expected, the presence of HUVECs did not significantly
affect the proliferation rates of T cells (Figures 4A,B). Contrarily,
hAACs and MSCs efficiently reduced the percentage of
proliferating CD4+ and CD8+ cells, exclusively after IFNγ
triggering, below 10% (Figures 4A,B). A slight reduction in T
cell proliferation was observed with unstimulated adherent cells,
but these changes were in fact not significant. Experimental
settings were repeated with hAACs under transwell conditions to
test for contact-dependency of the observed immunomodulatory
effects. No changes in proliferation of CD4+ and CD8+ T
cells were detectable with unstimulated hAACs in the transwell
setting. Pre-stimulation with IFNγ on the other hand caused
significant reduction of proliferation levels in both T cell
subsets (Figure 4C). The same trend was observed with a
significant decrease of the activation marker CD25 on CD4+
and particularly CD8+ T cells after IFNγ pre-stimulation
(Supplementary Figure 8).
Furthermore, a significant decrease of IFNγ and TNFβ
concentration was measured in co-cultures with unstimulated
and IFNγ-stimulated hAACs, but only the latter showed a
significant reduction in the amount of released TNFα, MDC,
IL-10, and IL-17A. Interestingly, co-cultures with unstimulated
hAACs produced significantly more IL-1β and less IL-2
(Figure 4D). Other cytokines measured like IL-5 and IL-13
showed significantly lower levels in IFNγ stimulated co-cultures
(data not shown).
Stimulation by IFNγ Leads to Specific
Changes in the Gene Expression Profile
of hAACs
Whole genome gene expression of unstimulated and IFNγ
pre-stimulated hAACs were analyzed on human hgu133plus2
microarrays (Affymetrix). Data were normalized and the 1000
most variable probe sets were used in a principle component
analysis. This unbiased analysis revealed a strong separation
of unstimulated and IFNγ pre-stimulated samples along the
first principle component reflecting the experimental design.
In addition, samples were separated according to different
hAAC donors in the principle component two, indicating
some heterogeneity of gene expression (Figure 5A). Although
showing these individual characteristics in gene expression,
additional analyses with Raman spectroscopy revealed a
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FIGURE 4 | IFNγ pre-stimulation enhances the immune-modulatory capacity of hAACs. CFSE-labeled PBMCs were activated with anti-CD3/anti-CD28 antibodies
(+αCD3/αCD28) and cultured alone (Control) or in the presence of unstimulated or IFNγ-stimulated hAACs, HUVECs or MSCs for 72 h. Cells were harvested, stained
(Continued)
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FIGURE 4 | with human-specific antibodies and analyzed by flow cytometry for T cell proliferation, based on reduced CFSE signal intensity. Percentages of CD4+ or
CD8+ proliferated cells for all experimental groups are shown as representative dot plots (A) and as summarized data with mean ± SEM (B) (n = 6–9; four
independent experiments with seven different hAAC donors). (C) Experimental settings were repeated with hAACs under transwell culture conditions to evaluate a
contact-dependent mode of action in the observed immune-modulatory effects (n = 7; three independent experiments with six different hAAC donors). (D)
Supernatants of the direct immune cell co-cultures with either unstimulated or IFNγ-treated hAACs were analyzed with a Luminex bead kit for their content of IFNγ,
TNFα, TNFβ, MDC, IL-1β, IL-2, IL-10, and IL-17A. Summarized data for cytokine concentrations [pg/mL] are presented as mean ± SEM (n = 6; three independent
experiments with six different hAAC donors). Groups were considered significantly different when *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 with Kruskal Wallis ANOVA and
Dunn’s post-test.
similar global phenotype of the hAAC cell product with no
detectable differences in the molecular composition of cells
derived from three hAAC donors (Supplementary Figure 9).
Next, differentially expressed genes between the unstimulated
and IFNγ pre-stimulated groups were determined by fitting
linear models to the data and running a Bayesian statistic.
Despite the genetic heterogeneity of the donors, a common
response to IFNγ can be identified as shown in the heatmap
(Figure 5B). Differentially expressed genes were subjected to an
overrepresentation analysis utilizing the gene ontology system.
The eight top-ranking results of the category “biological process”
are shown in Figure 5C and were related to the immune
system, cytokine-signaling and according to the experimental
setup to the IFNγ-response. Remarkably, much more genes were
up-regulated as down-regulated in the gene sets matched to
these GO-terms. The whole results of the overrepresentation
analysis are summarized in Supplementary Table 3. To identify
a common mode of action among the hAAC donors after
IFNγ pre-stimulation, the results of the genome-wide gene
expression profile were checked for differential expression of
known immunomodulatory genes in MSCs, including: IDO1,
PD-L1, PD-L2, NT5E, TGFB1, PTGES2, HGF, IGF, TNFAIP6,
JAG1, ICOSLG, HLA-G, PGE2, IL-10, LDHB, LDHA, LGALS1,
LGALS9, TLR3, ANXA1, VCAM1, PTGS1, PTGS2 and LIF.
However, only IDO1, LGALS9, TLR3, PD-L1, PD-L2, PTGS1,
HLA-G, and VCAM1 were differentially expressed among all
three donors and were therefore validated by qPCR. The analysis
of the relative gene expression normalized to the corresponding
unstimulated hAAC sample showed a very strong upregulation of
IDO1 expression in IFNγ-triggered hAACs. Yet, other immune
regulatory genes like LGALS9 (Galectin-9),TLR3, HLA-G, PTGS1
(COX-1) as well as PD-L1 and PD-L2 also showed a distinct
upregulation in the presence of IFNγ, but admittedly to a much
lesser extent (Figure 5D).
IDO Predominantly Mediates
Immunomodulation by IFNγ-Triggered
hAACs and Acts Through Apoptosis of
T Cells
Since IDO1 was by far the most upregulated gene in IFNγ
pre-stimulated hAACs (Figure 5D) and PD-L1/PD-L2 were
already described in the literature as a key mechanism of
action in cardiac-derived cells (30) and MSCs (45), we selected
them as promising molecules that might be involved in the
observed immunomodulatory potential of hAACs (Figure 4B).
As illustrated in Figure 6A, hAACs were cultured for 48 h in the
presence or absence of IFNγ. Following 2 h of pre-incubation
with 1-MT as a specific inhibitor of IDO or 12 h with blocking
antibodies against PD-L1 and PD-L2 (αPD1-ligand), either CFSE
labeled or unlabeled PBMCs were added to the cultures and
were subsequently activated with a cocktail of αCD3/αCD28
antibodies. After 72 h, PBMCs were analyzed by flow cytometry
to determine proliferation and apoptosis of T cells.
hAACs without treatment by blocking agents confirmed the
observed immunomodulatory effects by significantly inhibiting
T cell proliferation after IFNγ pre-stimulation, shown as relative
proliferation normalized to the αCD3/αCD28 PBMC control
(Figure 6B). Additionally, significantly higher levels of late-
apoptotic T cells occurred in IFNγ pre-stimulated co-cultures,
shown as relative percentages of Annexin-V+7-AAD+ T cells
normalized to the αCD3/αCD28 PBMC control (Figure 6C).
Treatment with blocking antibodies against both PD-1 ligands
neither had a significant effect on proliferation (Figure 6B),
nor on apoptosis rates (Figure 6C) of CD4+ and CD8+ T
cells when compared to the untreated control group. Notably,
treatment with 1-MT, mediating the blocking of IDO, resulted
in significant restoration of T cell proliferation in IFNγ-
stimulated hAAC co-cultures. However, unstimulated cultures
displayed rather reduced proliferation rates for both T cell subsets
(Figure 6B). Complementary to the proliferation, treatment
with 1-MT also caused significant reduction of Annexin-V+7-
AAD+ late-apoptotic T cells for the IFNγ hAAC group relative
to the untreated control group (Figure 6C). Yet, comparing
unstimulated hAACs with IFNγ hAAC under 1-MT treatment
illustrates, that levels were still elevated for apoptotic CD4+
cells, but were in fact not significantly different for the CD8+
subset (Figure 6C).
DISCUSSION
Based on the limited treatment options for cardiovascular
diseases, the development of new and potent cellular therapeutics
has emerged in the past decade as a promising new strategy aimed
at preventing or even reversing myocardial damage.
A huge variety of cell therapy studies had been conducted
withMSCs of different tissue origins, which reported onlymodest
or no significant efficacy to improve cardiac function (46). The
initial enthusiasm faded and a multitude of scientific questions
remained unanswered (47). Apart from developing solutions
for patient selection, timing of administration and appropriate
application routes including scaffold-based approaches, efficient
cell pre-conditioning or genetic manipulation (24), the most
pressing task is the identification of an isolation procedure for a
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FIGURE 5 | Whole genome expression analysis and quantitative verification of immunomodulatory gene expression of unstimulated and IFNγ pre-stimulated hAACs.
(A) Microarray expression data of unstimulated and IFNγ-stimulated hAACs were normalized and log2-transformed. Thousand probe sets with the highest variances
across all samples were selected and used in a principle component analysis, showing PC1 vs. PC2 for n = 3 hAAC donors (#1, #4, #5). (B) Differentially expressed
probe sets were determined by fitting linear models to the data and apply Bayesian statistics. P-values were adjusted for multiple testing using false discovery rate.
Probe sets with an adjusted p-value below.05 and a minimal absolute log2-foldchange of 1 are shown in the heatmap. The blue column bar indicates the unstimulated
and the red bar the IFNγ pre-stimulated hAACs of donors #1, #4, #5. (C) Differentially expressed probe sets were used in an overrepresentation analysis utilizing the
gene ontology system. The eight top-ranking results of the category biological process are shown. (D) The differentially expressed immunomodulatory genes IDO1,
LGALS9, TLR3, PD-L1, PD-L2, HLA-G, PTGS1 and VCAM1, identified in the global microarray analysis, were validated by qPCR. Values of IFNγ pre-stimulated
hAACs were normalized to the unstimulated samples (set to 1; black dotted line) by means of a 11Ct analysis and upregulation is shown as mean of relative
expression ± SEM for n = 3 hAAC donors (#1, #4, #5).
suitable and effective cell type. In this context, cells isolated from
close origin to the target tissue seem to be the most promising
cell therapeutic strategy (48, 49). Therefore, cardiac-derived cell
types excelled as a potentially powerful cell source due to their
known cardio-protective and pro-angiogenic effects. Due to the
lack of scientific evidence and understanding regarding these
positive effects of cell-based therapies, a return to the bench-side
would not only help to understand the mode of action, but also
may lead to a more reliable and effective therapy for the patient
(12). Moreover, large batches of healthy and instantly available
cells are needed for the realization of a broad and less expensive
clinical application, which clearly favors allogeneic cell sources.
To exclude any unwanted immunogenicity, especially under an
inflammatory and disease-related condition, it is indispensable
to analyze the interaction with immune cells in vitro. In the
present study, we addressed these issues by analyzing first the
main immunological characteristics of the allogeneic hAAC
cell product to estimate its immunogenicity and secondly by
investigating the immunomodulation capacity focusing on T
cell responses.
We could convincingly show that human allogeneic cells
from the right atrial appendage (hAACs) exhibit, even in an
inflammatory environment, an inherently low immunogenicity,
as demonstrated by the absence of adversely induced T cell
responses in immune cell co-cultures. Moreover, we could clearly
present that hAACs are effective modulators of already induced
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FIGURE 6 | Inhibition of T cell proliferation by hAACs is indoleamine-2,3-dioxygenase (IDO)-dependent and involves apoptosis. (A) The experimental setup to evaluate
the potential involvement of IDO and programmed death-1 (PD-1) ligands in hAAC effects on T cells is shown schematically: hAACs were seeded and stimulated with
IFNγ or left unstimulated for 48 h. Before co-cultivation with immune cells, 1-mehtyl-L-tryptophan (1-MT) as specific inhibitor of IDO or blocking antibodies against
PD-L1 and PD-L2 (αPD1 ligands) were applied. Subsequently, either CFSE-labeled or unlabeled PBMCs were activated by adding a cocktail of anti-CD3/anti-CD28
(+αCD3/αCD28) antibodies and left alone as controls or cultured with hAACs for 72 h. CD4+ or CD8+ T cell proliferation levels as well as the percentage of
Annexin-V+ (Av+) 7-AAD+ late apoptotic cells were determined by flow cytometry. (B) The normalized proliferation values for CD4+ or CD8+ T cell subsets were
calculated based on the respective PBMC controls and are presented as mean ± SEM (n = 6–10; four independent experiments with seven different hAAC donors).
(C) The normalized percentages of late-apoptotic Annexin-V+ (Av+) 7-AAD+ cells within the CD4+ and CD8+ T cell subsets were calculated based on the respective
PBMC controls and are presented as mean ± SEM (n = 6; two independent experiments with six different hAAC donors). Unstimulated (hAAC) and IFNγ-stimulated
hAACs (IFNγ hAAC) within the same treatment were considered significantly different when *p ≤ 0.05; **p ≤ 0.01 with the Mann-Whitney t-test. Differences between
treatments were considered significant when #p ≤ 0.05; ##p ≤ 0.01 with Kruskal Wallis ANOVA and Dunn’s post-test.
immune cell responses by suppressing T cell proliferation and
pro-inflammatory cytokine release, especially after triggering
with IFNγ. We could additionally show that IDO is one of the
key mediators responsible for the observed immunomodulating
features of hAACs. Our data strongly support the use of these
allogeneic cardiac-derived cells for the therapeutic application in
cardiovascular diseases.
So far, application of allogeneic cells for therapeutic
approaches was only taken into account for mesenchymal
cell types, like mesenchymal stromal cells (MSC) and cardiac
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progenitor cells (CPC) due to their known low immunogeneic
phenotype (22, 25, 50, 51). Therefore, we checked our newly
described hAAC cell product for the presence of characteristic
mesenchymal cell markers and could confirm a similar
expression pattern as seen in MSCs, with the only exception of a
significantly reduced CD90 expression. A low CD90 expression
might be an advantage for future therapeutic approaches by
reducing fibrosis, as shown in a prospective analysis of a
clinical trial using cardiosphere-derived cells (33). Inversely,
another study using human tissue revealed that CD90 expressing
fibroblasts are mainly responsible for the fibrotic thickening in
peritoneal dialysis patients (52).
However, more important for the clinical application of
an allogeneic cell product is to determine its potential
immunogenicity (53, 54) by evaluating the expression of
immunological markers under constitutive and inflammatory
conditions. In the present study, we could clearly demonstrate
that hAACs constitutively expressed HLA-ABC and partially
HLA-E, but not HLA-DR as well as the main co-stimulatory
molecules CD80 and CD86. After IFNγ stimulation, the
expression profile shifted toward a further increased expression
level of HLA-class I molecules and de novo induction
of HLA-DR expression. Yet, the co-stimulation molecules
remained absent. Additionally, hAACs showed expression of
the immunomodulatory molecules PD-L1 and PD-L2 on a
considerable proportion of cells that was further enhanced after
inflammatory stimulation. Comparatively, this surface marker
profile was already described for MSCs (45, 55, 56) and related
cardiac cell types (30, 57).
Despite the upregulated expression of both classes of HLA-
molecules after IFNγ stimulation, hAACs evaded an adaptive
immune response and were thereby not able to trigger substantial
CD4+ and CD8+ T cell proliferation, when co-cultured with
human PBMCs. The in parallel tested human MSCs induced a
similar proliferation response pattern in T cells. Although these
results might suggest the conclusion that hAACs andMSCs share
a common mode of action, they clearly differed in the spectrum
of secreted cytokines within PBMC co-culture supernatants.
Whereas, unstimulated and IFNγ stimulated MSCs and hAACs
did not induce any TNFα release, only the cardiac mesenchymal-
like hAACs showed significantly enhanced induction of the
anti-inflammatory cytokine IL-10 in both conditions. However,
it is striking, that exclusively IL-1ß and IL-33 levels were
significantly higher in co-cultures with hAACs, which exceeded
the constitutive secretion of both cytokines by hAACs alone. So
far it is unclear, which effects both cytokines of the IL-1 family
would have after transplantation of hAACs in a therapeutic
setting. It is known that they are classical pro-inflammatory
factors with an ambivalent function. On the one hand, IL-1β
secretion of MSCs is involved in monocyte dependent regulation
of CD4+ and CD8+ T cell activation by triggering the release of
TGFβ (58). IL-33, on the other hand, could play an important
role in cardiac tissue preservation and repair in response to
myocardial injury (59–62).
Our results regarding the induction of immune cell responses
with CD90low hACCs are comparable to data described for
CD90+ allogeneic human CPCs (30). Therefore, the expression
or absence of CD90 on cardiac-derived cells apparently seems
to be of inferior importance for the immunogenicity of the
respective allogeneic cell product. However, in contrast to our
study Lauden et al. demonstrated a rather low, but significant
induction of CD4+ T cell proliferation. Consequently, they were
able to prove the induction of regulatory T cells in co-cultures of
purified CD4+ T cells with human CPCs.
For the potential clinical application of the hAAC cell product,
not only a low immunogenicity, but also the capacity to suppress
ongoing inflammatory immune responses is important, since it
is widely believed to be responsible for the adverse remodeling
after cardiac injury (63, 64). In co-cultures with human allogeneic
PBMCs, we were able to demonstrate the capacity of hAACs
as well as MSC controls to suppress CD4+ and CD8+ T
cell proliferation nearly to the same extent. Both cell types
inhibited T cell proliferation by trend if cells were cultured
under unstimulated conditions and strongly enhanced their
suppressive capacity after IFNγ pre-stimulation. The “licensing”
effect of IFNγ was already well-described by several groups
for MSCs from different sources (65–69). In contrast, no clear
similarities between human CPCs and MSCs were detectable
regarding the inhibitory capacity of T cell proliferation in
PHA stimulated immune cell cultures as well as in mixed
lymphocyte reaction settings (30). However, the experimental
design of our study relied on different cell sources and a
diverging setup of immune cell co-cultures, which might explain
varying results of the immunomodulation. The comparable
immunomodulatory efficacy of CD90low hAACs and the CD90+
control umbilical cord MSCs argues, that CD90 expression does
not play a fundamental role in our experimental setup. Although,
a potential correlation was described by others for human MSCs
derived from bone marrow, amnion and chorion (70), other
factors seem to determine the immunosuppressive features of this
specific hAAC product.
The high potency of hAACs to efficiently down-regulate
already ongoing immune responses was additionally confirmed
by a strong suppression of the pro-inflammatory mediators
IFNγ, TNFα, and IL-17A as well as IL-2 to a minor extent.
Again, these effects were further enhanced in co-cultures with
IFNγ-licensed cells. The typical induction of a shift from an
inflammatory toward a more anti-inflammatory secretion profile
was described for human MSCs (71–74) and for CPCs (25, 75).
However, presence of hAACs in triggered immune cell co-
cultures rather lowered anti-inflammatory cytokines like TGFß
and IL-10 instead of inducing those as described for MSCs
(58, 73, 76).
Next, we wanted to get a deeper understanding of the
molecular changes in hAACs after pre-stimulation with IFNγ
that are likely to be responsible for the immunosuppressive
or modulatory efficacy. For this, we compared unstimulated
and IFNγ stimulated hAACs in a whole genome analysis by
Affymetrix R© microarray technology and could determine similar
characteristics for all three donors between each treatment group,
despite visible biological heterogeneities in their individual RNA
profiles. More interestingly, the global analysis revealed, that
pathways of general immune system responses (innate and
adaptive), as well as cytokine signaling and IFNγ responses were
Frontiers in Immunology | www.frontiersin.org 15 July 2019 | Volume 10 | Article 1716
Diedrichs et al. Immunomodulation by Cardiac-Derived Mesenchymal Cells
FIGURE 7 | Potential crosstalk between hAACs and T cells in an inflammatory milieu. The scheme illustrates the impact of IFNγ stimulation on CD90low hAACs and
its implication on the interplay with αCD3/αCD28 activated human T cells. Stimulation of hAACs alone induces upregulation of HLA-class I (HLA-ABC, HLA-E) and de
novo expression of HLA-class II molecules (HLA-DR). Even though expression of the inhibitory co-stimulatory molecules PD-L1 and PD-L2 is enhanced on the cell
surface, no specific effects in the interaction with activated T cells were detectable. Similarly, the role of the specific secretion of IL-1 family cytokines (IL-1β, IL-33) by
hAACs and additional unknown mediators like exosomes remain unclear. However, a global genome-wide expression profile analysis revealed IDO as one of the
strongest expressed genes in IFNγ stimulated hAACs. Specific blocking by 1-MT proved the essential involvement of IDO in the interaction with T cells. It mediates the
suppression of CD4+ and CD8+ T cell proliferation, reduces the secretion of pro-inflammatory cytokines (IFNγ, TNFα, TNFβ, IL-17A) and induces apoptosis of both T
cell subsets. We hypothesize, that this mode of hAAC interaction might contribute to the resolution of immune responses and limit thereby the effects of adverse
remodeling after cardiac injury.
preferentially involved. A closer look into specific, immune-
relevant molecules, that were significantly up-regulated under
IFNγ stimulation, exposed IDO1 as one of the strongest
expressed genes among other interesting candidates, such as
LGALS9 (Galectin-9), TLR3, HLA-G, PTGS1 (COX-1). The
particularly high degree of IDO1-upregulation in IFNγ pre-
stimulated hAACs was also confirmed by qPCR. IDO is often
discussed to be involved in immunosuppressive effects exerted
by MSCs on T cells by depletion of tryptophan and accumulation
of metabolites like kynurenin (77–81). In correlation with the
strong up-regulation of IDO, we could prove the involvement of
this particular molecule in the suppression of T cell proliferation
and the induction of their apoptosis by application of the specific
inhibitor 1-MT. These observations are in accordance with a
recent study, which correlated the suppressive capacity of IFNγ
licensed MSCs on third party T cell proliferation to enhanced
IDO and PD-L1 expression (82).
Interestingly, PD-L1 and PD-L2 were found to be up-
regulated on RNA and protein level in hAACs after inflammatory
stimulation. The interaction of these twomolecules with PD-1 on
T cells might also contribute to the observed immunosuppressive
effects. For bone marrow MSCs it was recently demonstrated
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that the expression and secretion of both PD-1 ligands mediated
suppression of CD4+ T cell activation, down-regulated IL-
2 secretion and induced hypo-responsiveness and cell death
in T cells (45). However, in our experimental settings the
application of blocking antibodies against both PD-1 ligands
could neither reverse the suppression of T cell proliferation
nor prevent the induction of apoptosis. We also found,
that IFNγ pre-stimulated hAACs showed nearly the same
suppression of αCD3/αCD28-induced T cell proliferation in
direct contact as well as transwell settings. That implies that
hAACs mainly mediate their immunomodulatory effects in an
inflammatory milieu by soluble factors or vesicles that are
able to cross the transwell membrane. A paracrine mode of
action has often been suggested by others for MSCs and related
mesenchymal cell types (83–86). The missing blocking effect
of PD-1 ligands, which are secreted and also expressed on
the cell surface, clearly discriminates hAACs from the before
mentioned CD90+ CPCs, that exert a more contact-dependent
mode of suppression by PD-L1 involvement on ongoing immune
responses (30). Conclusively, the observed increase of PD-
L1 and PD-L2 expression on the cell surface seems to play
only an inferior role in the immune regulation mediated by
hAACs. Even though their general cellular characteristics are
clearly distinguishable from fibroblasts and conventional MSCs
(32), hAACs behave more like MSCs in this immunological
context. The importance of the observed up-regulation of other
potential immunoregulatory genes such as Galcetin-9 for the
immunomodulatory capacity of hAACs has to be analyzed in
more detail in future studies.
There are also still open questions remaining regarding
the nature of how hAACs avoid unwanted immune responses
in clinically relevant settings of cardiac injury. Apart from
the proved involvement of IDO in the efficient T cell
immunosuppression under IFNγ treatment, the interaction of
antigen-presenting cells, like monocytes, has also to be taken
into account. In this regard, it became evident that MSCs
could skew monocytes toward anti-inflammatory macrophages
(87–89) and induce the generation of regulatory T cells (58,
76). Additionally, it was found that MSCs could be taken
up by monocytic cells and induce changes toward a non-
classical monocyte phenotype with enhanced expression of
PD-L1 and secretion of IL-10 that subsequently modulates
adaptive immune responses (90). Furthermore, it was recently
published that human CPCs attracted monocytes by a set of
released cytokines and mediators and consequently changed
the polarization of differentiating macrophages toward an
M2-type cell (25, 91). Future studies will therefore focus
on this hAAC/antigen-presenting cell interplay to gain a
better understanding of the underlying mechanism of action
and ensure the safe and effective translation of this hAAC
cell product.
In the present study we could show, that CD90low hAACs
isolated from human heart tissue represent a new allogeneic
off-the-shelf mesenchymal-like cell product with therapeutically
interesting features. Most importantly, hAACs do not trigger
immunogeneic effects based on the low expression of HLA-DR
and absence of co-stimulatory molecules after pro-inflammatory
IFNγ stimulation. Moreover, hAACs clearly demonstrated a
strong potential to inhibit ongoing immune responses even
in inflammatory environments. Ultimately, we could illustrate
that IDO-upregulation under IFNγ pre-treatment seems to be
one of the most important players mediating the observed
suppressive effects (Figure 7). However, the involvement of other
so far not identified soluble factors cannot be excluded. This
paracrine mode of action would also suggest the opportunity to
isolate and use extracellular vesicles derived from hAACs for a
clinical application. Our data in general would argue for a safe
application of the hAAC cell product in an allogeneic setting,
which also facilitates high potential to suppress already ongoing
immune responses and thereby limit the progression of adverse
remodeling after cardiac injury.
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